Evidence map›Paper›PMID 38807606›Full record

ArticleFrontiers in immunology2024

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.

Kilian A Wietschel, Kevin Fechtner, Elmer Antileo, Goran Abdurrahman, Chiara A Drechsler, Michelle Kudzayi Makuvise, Ruben Rose, Mathias Voß, Andi Krumbholz, Stephan Michalik and 7 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kilian A Wietschel *Institute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Kevin Fechtner *Institute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Elmer AntileoInstitute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Goran AbdurrahmanInstitute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Chiara A DrechslerInstitute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Michelle Kudzayi MakuviseInstitute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Ruben RoseInstitute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Mathias VoßInstitute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Andi KrumbholzInstitute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Stephan MichalikInterfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany.
Stefan WeissInterfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany.
Lena UlmFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Philipp FranikowskiInstitute for Educational Quality Improvement, Humboldt University of Berlin, Berlin, Germany.
Helmut FickenscherInstitute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Barbara M BrökerInstitute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Dina Raafat *Institute of Immunology, University Medicine Greifswald, Greifswald, Germany.
Silva Holtfreter *Institute of Immunology, University Medicine Greifswald, Greifswald, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19 vaccines are highly effective in inducing protective immunity. While the serum antibody response to COVID-19 vaccination has been studied in depth, our knowledge of the underlying plasmablast and memory B cell (Bmem) responses is still incomplete. Here, we determined the antibody and B cell response to COVID-19 vaccination in a naïve population and contrasted it with the response to a single influenza vaccination in a primed cohort. In addition, we analyzed the antibody and B cell responses against the four endemic human coronaviruses (HCoVs). Methods: Measurement of specific plasma IgG antibodies was combined with functional analyses of antibody-secreting plasmablasts and Bmems. SARS-CoV-2- and HCoV-specific IgG antibodies were quantified with an in-house bead-based multiplexed immunoassay. Results: The antibody and B cell responses to COVID-19 vaccination reflected the kinetics of a prime-boost immunization, characterized by a slow and moderate primary response and a faster and stronger secondary response. In contrast, the influenza vaccinees possessed robust immune memory for the vaccine antigens prior to vaccination, and the recall vaccination moderately boosted antibody production and Bmem responses. Antibody levels and Bmem responses waned several months after the 2 Discussion: Overall, by complementing classical serology with a functional evaluation of plasmablasts and memory B cells we provide new insights into the specificity of COVID-19 vaccine-induced antibody and B cell responses.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesCross ReactionsImmunity, HumoralImmunoglobulin GMemory B CellsPlasma CellsSARS-CoV-2AdultAntibodies, NeutralizingB-LymphocytesEpitopes, B-LymphocyteFemaleHumansImmunologic MemoryAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopes, B-LymphocyteImmunoglobulin GInfluenza VaccinesSpike Glycoprotein, CoronavirusCOVID-19 vaccinationcross-reactive antibodiesdynamicsHCoVinfluenzamemory B celloriginal antigenic sinplasmablast

Identifiers

PMID38807606
PMCPMC11130424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.